Merck, Pfizer launch Bavencio for rare skin cancer

Merck and Pfizer have launched in the UK of Bavencio, the first medicine to be licensed for the treatment of the rare, aggressive skin cancer of metastatic Merkel Cell Carcinoma (mMCC).

• Source: Pharmatimes
• 488
• November 7, 2017